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Abstract
Estimating the consequences and the cost of methicillin resistance
is a difficult challenge. Patients who develop methicillin-resistant
ventilator-associated pneumonia (VAP) are very different from
those who develop methicillin-sensitive VAP, and biased estimates
are frequent. We reviewed some important confounding factors of
which the reader should be aware.
In the previous issue of Critical Care, Shorr and coworkers
[1] provided new data on the morbidity and cost burden
attributable to methicillin-resistant Staphylococcus aureus
(MRSA)-associated early-onset pneumonia (EOP). Based on
the data recorded by 42 US hospitals, those investigators
found methicillin resistance to be associated with a
significant 4- to 6-day excess in mechanical ventilation, and
intensive care unit (ICU) and in-hospital days. It was
associated with a nonsignificant increase of about US$8000
in total costs, after controlling for case mix and severity. The
authors made particular effort to select monomicrobial
pneumonias and to adjust the calculations based on
underlying illness, and on the severity and duration of ICU
stay before EOP. However, this estimated increase in costs
should be regarded with caution because of a number of
potential biases associated with this type of analysis.
First, the observed incidence of EOP was very low. The
overall risk for ventilator-associated pneumonia (VAP) is
between 9.7% and 22.8% [2]. EOP represents at least one-
third of cases. Consequently, the rate of EOP should be
higher than 3.2% [3]. Because Shorr and coworkers found
that only 499 episodes were recorded in 42 hospitals over
2 years, this suggests that the incidence was unusually low or
that EOP was largely under-reported. This could have
introduced bias because unrecognized episodes might be
different (probably less severe) than reported ones. Any
under-recognition of EOP might have resulted from the
known lack of reproducibility of ICD-9 (International
Classification of Diseases, ninth edition) [4]. Moreover,
MRSA VAP has been reported to occur mainly late in the ICU
stay [5-8]; MRSA represents fewer than 5% of micro-
organisms encountered in EOP episodes [9]. The factors that
impact on outcomes of EOP may be different from those in
late-onset pneumonia [9,10]. For example, EOP is associated
a shorter ICU stay, with significantly fewer days of mechanical
ventilation, of central vein catheterization and of use of ICU
resources [9]. This fact probably largely explained why the
ICU length of stay (4 days) was considerably lower in the
report by Shorr and coworkers than in the recent report by
Combes and coworkers (i.e. 11 days) [5].
Second, MRSA and methicillin-sensitive Staphylococcus
aureus (MSSA) EOP were not matched for the same
hospital, and therefore variability in charges between
hospitals could account for some of the observed differ-
ences. Surprisingly, the authors found that the ICU resources
and extra costs related to MRSA EOP were higher only for
survivors, as opposed to MSSA EOP. On the contrary,
deaths occurred earlier in fatal MRSA EOP, leading to lower
hospital costs for nonsurvivors. Because MRSA VAP has not
been associated with higher rates of organ dysfunction than
MSSA VAP [5], the potential causes of this finding are
speculative (e.g. differences in the rate of do-not-resuscitate
orders, differences in case mix, differences in the adequacy of
antimicrobial treatment, or chance) and might have had a
confounding impact on the final result.
Despite these limitations, economic studies such as that
conducted by Shorr and coworkers [1] provided further
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evidence of the cost of MRSA infections and provide new
arguments for funding the fight against MRSA spread in the
ICU.
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